Clinical Trial Update: Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating anti-PD-1 antibody in combination with DEB-TACE for hepatocellular carcinoma (BCLC A/B).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anti-PD-1 antibody
• DEB-TACE

Snippet

Sponsor: Zhejiang University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN